U.S. markets open in 3 hours 26 minutes

Context Therapeutics Inc (6K9.BE)

Berlin - Berlin Delayed Price. Currency in EUR
0.9700+0.0050 (+0.52%)
As of 10:50AM CEST. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9650
Bid0.8850 x N/A
Ask0.0000 x N/A
Day's Range0.9700 - 0.9700
52 Week Range0.4360 - 1.5200
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for 6K9.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • News Direct

      Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update

      Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76.

    • GlobeNewswire

      Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

      Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming

    • GlobeNewswire

      Context Therapeutics to Participate in Two August 2023 Investor Conferences

      PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023. Details of the events are as follows: BTIG Virtual Biotechnology Conference 2023: Context CEO Martin Lehr will participate in a fireside chat taking place on Mo